Leading the company with the only therapy approved for NTM lung disease, Will Lewis tells In Vivo that success comes from giving researchers room to breath, visualizing patient benefit, and sailing into uncharted waters.

In Vivo talked to two organizations making progress in the diagnosis of rare diseases using software and genomic sequencing.

Resetting requirements for jobs, with the importance of degrees and higher education lessened in favor of appropriate skills and talent, is a trend that could hugely benefit both employers and staff over the next ten years, creating a skills-based economy in which all members can thrive to counter the Great Resignation.

Agios’s Sarah Gheuens talks to In Vivo about the responsibility of providing new therapies to rare disease populations, building trust with historically underserved communities, and why she loves working with small molecules.

Sharing his thoughts on the European funding landscape, the importance of software, and sustainable investments, INKEF Capital’s Thijs Cohen Tervaert talks to In Vivo about his investment priorities.

Digital health platforms that offer personalized support are gaining traction in the market, both from patients and investors. Trellus Health is connecting IBD patients with resilience methodologies that enable disease management at lower healthcare costs. Its co-founder Laurie Keefer talks to In Vivo about scaling up the business for greater reach within the market.